FILE 'HOME' ENTERED AT 18:53:42 ON 20 JUN 2009

=> b ca

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

FULL ESTIMATED COST

ENTRY SESSION 0.22 0.22

FILE 'CA' ENTERED AT 18:54:00 ON 20 JUN 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2009 VOL 150 ISS 26
FILE LAST UPDATED: 18 Jun 2009 (20090618/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Arp 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

 ${\tt CA}$  now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s apml or adiponectin 173 APM1

5472 ADIPONECTIN

.1 5556 APM1 OR ADIPONECTIN

=> s 11 and polyclonal antibod?

40047 POLYCLONAL 542111 ANTIBOD?

20073 POLYCLONAL ANTIBOD?

(POLYCLONAL (W) ANTIBOD?)

L2 15 L1 AND POLYCLONAL ANTIBOD?

=> s 12 and native(w)(apml or adiponectin) 156938 NATIVE

173 APM1

```
2 NATIVE(W) (APM1 OR ADIPONECTIN)
             0 L2 AND NATIVE(W) (APM1 OR ADIPONECTIN)
=> s 12 and native
        156938 NATIVE
             0 L2 AND NATIVE
=> s 12 and latex
         75640 LATEX
             2 L2 AND LATEX
=> d ti ab 1-2
     ANSWER 1 OF 2 CA COPYRIGHT 2009 ACS on STN
     Determination of ***adiponectin*** in serum using a ***latex***
ΤI
     particle-enhanced turbidimetric immunoassav with an automated analyzer
      ***Adiponectin*** is an adipose-derived hormone that plays a role in
AB
     regulating metabolic processes such as fat partitioning and lipid and
     qlucose metab. Quantification of ***adiponectin*** is useful for
     obtaining information on metabolic syndrome, but there is no rapid method
     to measure ***adiponectin*** for clin. use. The authors developed a
     rapid and sensitive ***latex*** particle-enhanced turbidimetric
     immunoassay (LTIA) using a ***latex*** bead-immobilized anti-
***adiponectin*** ***polyclonal*** ***antibody*** . The assay
     was performed on a Hitachi H7170 analyzer and evaluated for validity as a
     method to quantitate ***adiponectin*** , in parallel with the ELISA.
     Diln. tests using LTIA showed linearity from 0.25 to 30 .mu.g/mL.
     Within-run CV and total CV were obtained in the range 0.8-1.9% and
     1.1-2.0%, resp. No interference was obsd. in the testing of specimens
     contq. potentially interfering substances such as bilirubin,
```

5472 ADIPONECTIN

L5 ANSWER 2 OF 2 CA COPYRIGHT 2009 ACS on STN

and suitable for clin. routine anal.

TI \*\*\*Latex\*\*\* reagent for \*\*\*adiponectin\*\*\* analysis, and

\*\*\*adiponectin\*\*\* analysis method

AB A \*\*\*latex\*\*\* reagent for \*\*\*adiponectin\*\*\* anal. is provided,
which comprises a suspension of \*\*\*latex\*\*\* particles carrying a
substance (e.q., anti- \*\*\*adiponectin\*\*\* \*\*\*polyclonal\*\*\*

ditaurobilirubin, Hb triglyceride, rheumatoid factor, type IV collagen, fibronectin, and complement factor (Clq). A strong correlation between LTIA and ELISA was confirmed (n = 30, r = 0.990, y = 0.95x + 0.39). The LTIA assay is applicable to quantitating the serum concn. of

\*\*\*adiponectin\*\*\* . This assay is more convenient and faster than ELISA

\*\*\*antibody\*\*\* ) capable of specifically binding with \*\*\*adiponectin\*\*\*

. Also provided is a method for \*\*\*adiponectin\*\*\* anal., which comprises: (1) a step for obtaining a biol. liq. potentially contg. \*\*\*adiponectin\*\*\* ; and (2) a step for contacting the biol. liq.

obtained in the step (1) as it is with a suspension of \*\*\*latex\*\*\* particles carrying a substance capable of specifically binding with

\*\*\*adiponectin\*\*\* , and optically analyzing the resultant mixt. to det. the degree of agglutination of the \*\*\*latex\*\*\* particles. According to this \*\*\*latex\*\*\* reagent for \*\*\*adiponectin\*\*\* anal. and this \*\*\*adiponectin\*\*\* anal. method, it is not required to dil. or pretreat

а

biol. liq. as a test sample beforehand, and the anal. is rapidly and conveniently performed without limiting a measurement facility.

```
ANSWER 1 OF 2 CA COPYRIGHT 2009 ACS on STN
    145:391809 CA <<LOGINID::20090620>>
AN
ED
    Entered STN: 02 Nov 2006
    Determination of ***adiponectin*** in serum using a ***latex***
TI
    particle-enhanced turbidimetric immunoassay with an automated analyzer
TIA
    Nishimura, Avako; Sawai, Tokio
CS
    Division of Research and Development, Mitsubishi Kagaku Iatron Inc.,
    1460-6 Mitodai, Tako-machi, Katori-gun, Chiba-ken, 289-2247, Japan
SO
   Clinica Chimica Acta (2006), 371(1-2), 163-168
    CODEN: CCATAR: ISSN: 0009-8981
PB
   Elsevier Ltd.
DT Journal
LA English
CC 9-10 (Biochemical Methods)
AB
      ***Adiponectin*** is an adipose-derived hormone that plays a role in
    regulating metabolic processes such as fat partitioning and lipid and
    glucose metab. Quantification of ***adiponectin*** is useful for
    obtaining information on metabolic syndrome, but there is no rapid method
    to measure ***adiponectin*** for clin. use. The authors developed a
    rapid and sensitive ***latex*** particle-enhanced turbidimetric
    immunoassay (LTIA) using a ***latex*** bead-immobilized anti-
      was performed on a Hitachi H7170 analyzer and evaluated for validity as a
    method to quantitate ***adiponectin*** , in parallel with the ELISA.
    Diln. tests using LTIA showed linearity from 0.25 to 30 .mu.q/mL.
    Within-run CV and total CV were obtained in the range 0.8-1.9% and
    1.1-2.0%, resp. No interference was obsd. in the testing of specimens
    contg. potentially interfering substances such as bilirubin,
    ditaurobilirubin, Hb triglyceride, rheumatoid factor, type IV collagen,
    fibronectin, and complement factor (Clq). A strong correlation between
    LTIA and ELISA was confirmed (n = 30, r = 0.990, v = 0.95x + 0.39). The
    LTIA assay is applicable to quantitating the serum concn. of
      ***adiponectin*** . This assay is more convenient and faster than ELISA
    and suitable for clin. routine anal.
      ***adiponectin*** detn serum ***latex*** particle turbidimetric
    immunoassay automated analyzer; metabolic syndrome ***adiponectin***
    serum immunoturbidimetry automatic analyzer
    Cytokines
    RL: ANT (Analyte); ANST (Analytical study)
       ( ***adiponectin*** ; detn. of ***adiponectin*** in serum using
         ***latex*** particle-enhanced turbidimetric immunoassay with
       automated analyzer)
ΙT
    Blood analysis
    Human
    Immunoturbidimetry
    Metabolic disorders
```

(detn. of \*\*\*adiponectin\*\*\* in serum using \*\*\*latex\*\*\*
particle-enhanced turbidimetric immunoassay with automated analyzer)

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD

(1) Anon; JAMA 2001, V285, P2486

RE.CNT 24

RE

=> d all 1-2

```
(2) Arita, Y; Biochem Biophys Res Commun 1999, V257, P79 CA
(3) Arita, Y; Circulation 2002, V105, P2893 CA
(4) Bland, J; Lancet 1986, V1, P307 MEDLINE
(5) Daimon, M; Diabetes Care 2003, V26, P2015 CA
(6) Haluzik, M; Physiol Res 2004, V53, P123 CA
(7) Hansa, T; Clin Chem 1997, V43, P109
(8) Hotta, K; Arterioscler Thromb Vasc Med 2000, V20, P1595 CA
(9) Hotta, K; Diabetes 2001, V50, P1126 CA
(10) Kumada, M; Arterioscler Thromb Vasc Biol 2003, V23, P85 CA
(11) Lindsay, R; Lancet 2002, V360, P57 CA
(12) Lowry, O; J Biol Chem 1951, V193, P265 CA
(13) Maeda, K; Biochem Biophys Res Commun 1996, V221, P286 CA
(14) Maeda, K; Gene 1997, V190, P227 CA
(15) Okamoto, Y; Circulation 2002, V106, P2767 CA
(16) Okamoto, Y; Horm Metab Res 2000, V32, P47 CA
(17) Ouchi, N; Circulation 1999, V100, P2473 CA
(18) Ouchi, N; Circulation 2000, V102, P1296 CA
(19) Ouchi, N; Circulation 2001, V103, P1057 CA
(20) Ouchi, N; Hypertension 2003, V42, P231 CA
(21) Pauli, S; Clin Chem 2004, V50, P219
(22) Pischon, T; JAMA 2004, V291, P1730 CA
(23) Ryo, M; Circ J 2004, V68, P975 CA
(24) Tsukinoki, R; Lipids Health Dis 2005, V4, P27
1.5
    ANSWER 2 OF 2 CA COPYRIGHT 2009 ACS on STN
AN
    141:310247 CA <<LOGINID::20090620>>
ED
     Entered STN: 28 Oct 2004
       ***Latex*** reagent for
                                  ***adiponectin*** analysis, and
TΤ
       ***adiponectin*** analysis method
TN
     Tachikawa, Tetsuva; Akamatsu, Suguru; Sawai, Tokio; Nishimura, Fumiko
PA
    Mitsubishi Kagaku Iatron, Inc., Japan; Otsuka Pharmaceutical Co., Ltd.
SO
    PCT Int. Appl., 26 pp.
    CODEN: PIXXD2
DT
    Patent
LA
    Japanese
     ICM G01N033-53
IC
     ICS G01N033-543
CC
    9-10 (Biochemical Methods)
FAN.CNT 1
```

	PAT	PATENT NO.					D	DATE		APPLICATION NO.						DATE		
PI	WO	2004086040				A1	A1 20041007		WO 2004-JP4083						20040324			
		W:	ΑE,	AG,	AL,	AM,	ΑT,	AU,	ΑZ,	BA,	BB,	BG,	BR,	BW,	BY,	ΒZ,	CA,	CH,
			CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FΙ,	GB,	GD,
			GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KP,	KR,	KΖ,	LC,
			LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	ΜZ,	NA,	NI,
			NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SY,
			ΤJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
		RW:	BW,	GH,	GM,	KE,	LS,	MW,	ΜZ,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,
			BY,	KG,	ΚZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,
			ES,	FI,	FR,	GB,	GR,	HU,	IE,	IT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,
			SK,	TR,	BF,	ΒJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,
			TD,	TG														
	AU	2004223553				A1		20041007 AU 2004-223553							20040324			
	AU	2004223553				B2		2008	1204									
	CA	2520438				A1		2004	1007		CA 2004-2520438					20040324		
	EP	1607742			A1		2005	1	EP 2004-723044					20040324				

```
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
    US 20070037207 A1 20070215
                                       US 2005-550324 20050923
PRAI JP 2003-80763
                       A
                            20030324
    WO 2004-JP4083
                      W
                            20040324
CLASS
PATENT NO. CLASS PATENT FAMILY CLASSIFICATION CODES
  _____
WO 2004086040 ICM G01N033-53
               TCS
                     G01N033-543
               IPCI G01N0033-53 [ICM, 7]; G01N0033-543 [ICS, 7]
                IPCR G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-543
                      [I,C*]; G01N0033-543 [I,A]; G01N0033-68 [I,C*];
                      G01N0033-68 [I.A]
               ECLA G01N033/543D; G01N033/68V
               IPCI G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-543
AU 2004223553
                      [I,C*]; G01N0033-543 [I,A]; G01N0033-68 [I,C*];
                      G01N0033-68 [I,A]
                IPCR G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-543
                      [I,C*]; G01N0033-543 [I,A]; G01N0033-68 [I,C*];
                      G01N0033-68 [I,A]
               ECLA G01N033/543D; G01N033/68V
                IPCI G01N0033-53 [ICM, 7]; G01N0033-543 [ICS, 7]
CA 2520438
                IPCR G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-543
                      [I,C*]; G01N0033-543 [I,A]; G01N0033-68 [I,C*];
                      G01N0033-68 [I,A]
               ECLA G01N033/543D; G01N033/68V
EP 1607742
               IPCI G01N0033-53 [ICM, 7]; G01N0033-543 [ICS, 7]
               IPCR G01N0033-53 [I,C*]; G01N0033-53 [I,A]; G01N0033-543
                      [I,C*]; G01N0033-543 [I,A]; G01N0033-68 [I,C*];
                      G01N0033-68 [I,A]
               ECLA G01N033/543D; G01N033/68V
US 20070037207 IPCI G01N0033-53 [I,A]; G01N0033-551 [I,A]
               NCL 435/007.100; 436/524.000
   A ***latex*** reagent for ***adiponectin*** anal. is provided,
    which comprises a suspension of ***latex*** particles carrying a
    substance (e.g., anti- ***adiponectin*** ***polyclonal***
      ***antibody*** ) capable of specifically binding with
***adiponectin***
    . Also provided is a method for ***adiponectin*** anal., which
    comprises: (1) a step for obtaining a biol. lig. potentially contg.
      ***adiponectin*** ; and (2) a step for contacting the biol. lig.
obtained
    in the step (1) as it is with a suspension of ***latex*** particles
    carrying a substance capable of specifically binding with
      ***adiponectin*** , and optically analyzing the resultant mixt. to det.
    the degree of agglutination of the ***latex*** particles. According
    to this ***latex*** reagent for ***adiponectin*** anal. and this
      ***adiponectin*** anal. method, it is not required to dil. or pretreat
    biol. liq. as a test sample beforehand, and the anal. is rapidly and
    conveniently performed without limiting a measurement facility.
     ***adiponectin*** analysis ***latex*** agglutination reagent
ST
```

RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses) ( \*\*\*adiponectin\*\*\* anal. method using \*\*\*latex\*\*\* aqqlutination

antibody

ΙT

Antibodies and Immunoglobulins

```
immunoassay reagent)
IT Cytokines
    RL: ANT (Analyte); ANST (Analytical study)
       ( ***adiponectin*** ; ***adiponectin*** anal. method using
         ***latex*** agglutination immunoassay reagent)
TT
   Agglutination test
       ( ***latex*** ; ***adiponectin*** anal. method using
         ***latex*** agglutination immunoassay reagent)
      ***Latex***
       (particles; ***adiponectin*** anal. method using ***latex***
       agglutination immunoassay reagent)
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
(1) A&t Corp; JP 20014624 A 2001
(2) Otsuka Pharmaceutical Co Ltd; EP 1033134 A 1999 CA
(3) Otsuka Pharmaceutical Co Ltd; US 6461821 B 1999 CA
(4) Otsuka Pharmaceutical Co Ltd; WO 9921577 A 1999 CA
=> d his
    (FILE 'HOME' ENTERED AT 18:53:42 ON 20 JUN 2009)
    FILE 'CA' ENTERED AT 18:54:00 ON 20 JUN 2009
         5556 S APM1 OR ADIPONECTIN
T.2
            15 S L1 AND POLYCLONAL ANTIBOD?
L3
            0 S L2 AND NATIVE(W)(APM1 OR ADIPONECTIN)
L4
            0 S L2 AND NATIVE
L5
             2 S L2 AND LATEX
=> logoff y
                                               SINCE FILE
COST IN U.S. DOLLARS
                                                             TOTAL
                                                   ENTRY SESSION
FULL ESTIMATED COST
                                                   31.85
                                                             32.07
                                             SINCE FILE
                                                             TOTAL
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
                                                   ENTRY SESSION
CA SUBSCRIBER PRICE
                                                    -3.12
                                                              -3.12
STN INTERNATIONAL LOGOFF AT 18:56:58 ON 20 JUN 2009
```